Health Condition 1: C349- Malignant neoplasm of unspecifiedpart of bronchus or lung
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
Anil Tibdewal
Eligibility
Inclusion criteria
Inclusion criteria: 1)Patients with histopathological diagnosis of non-small cell lung cancer 2)Patients with age > 18 years 3)Patients with confirmed oligoprogression in 4)Patients with oligoprogression in 5)Patients with oligorecurrent disease at primary and/or regional nodal sites (previously covered in RT portal is allowed if can be treated radically again) with or without distant metastases in previously treated non-metastatic NSCLC. 6)Patients with metastatic NSCLC with all sites responding to systemic therapy (TKI/Chemotherapy/ICI) except few (1-3) â?? Oligopersistent diseases 7)Patient with completely resolved or stable pleural effusion is allowed but with no new onset malignant pleural or pericardial effusion 8)All sites must be amenable either by local ablative radiation therapy (with SBRT/ Radical RT - conventional or hypofractionated RT) or RFA or Surgery 9)At least one site should be treated with radiation therapy. Only RFA or Only Surgically treated patients will be excluded except patients with post-operative whole brain radiation therapy with or without boost or post-operative cavity stereotactic radiosurgery. 10)Adequate baseline organ function to allow LAT to all the OP, OR or Oligopersistent targets. 11)Karnofsky Performance status >= 60 and ECOG 0-2 (except patients with brain metastases where PS is declined solely due to brain s) 12)Provision of written informed consent
Exclusion criteria
Exclusion criteria: 1)Age 2) > 3 sites of oligoprogressive disease (except mentioned for intracranial sites only) 3)OP, OR and oligopersistence disease not amenable to LAT 4)Co-morbidities considered clinically precluding the safe use of LAT 5)Any psychological, sociological or geographical issue potentially hampering compliance with the study 6)Pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To estimate the progression free survival defined as the time from initiation of local ablative therapy till the date of second progression or death whichever is earlierTimepoint: 12 months | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to change of systemic therapy (time from LAT until initiation of next line systemic therapy or death) Timepoint: 12 months;Time to development of new sites of metastases Timepoint: 12 months | — |
Countries
India
Contacts
Public ContactAnil Tibdewal
Tata Memorial Hospital
Outcome results
None listed